Cargando…
Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence
Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy in humans, and as such it poses a significant healthcare burden. The majority of BCC cases are amenable to cure by surgical extirpation. However, until recently there have been no good treatment options for a significant minority o...
Autores principales: | Tay, Evelyn Yu-Xin, Teoh, Yee-Leng, Yeo, Matthew Sze-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380977/ https://www.ncbi.nlm.nih.gov/pubmed/30539424 http://dx.doi.org/10.1007/s13555-018-0277-7 |
Ejemplares similares
-
Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response
por: Gambini, Donatella, et al.
Publicado: (2022) -
Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma
por: Habashy, Suzanne, et al.
Publicado: (2021) -
Hedgehog pathway inhibitors – current status and future prospects
por: Sheikh, Asfandyar, et al.
Publicado: (2012) -
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors
por: Fecher, Leslie A, et al.
Publicado: (2015) -
Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
por: VERKOUTEREN, Babette J. A., et al.
Publicado: (2022)